Bleomycin Sulfate

Catalog No.S1214 Synonyms: NSC125066

Bleomycin Sulfate Chemical Structure

Molecular Weight(MW): 1512.62

Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.

Size Price Stock Quantity  
USD 170 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.
In vitro

UT-SCC-12A and UT-SCC-12B are both more resistant to Bleomycin sulfate with IC50 of 14.2 nM and 13 nM, respectively. [1] Alveolar macrophages incubated with 0.01 μg/mL to 1μg /mL Bleomycin sulfate for 18 hours secretes significantly more fibroblast growth factor than macrophages incubated without Bleomycin sulfate. Macrophages stimulated with Bleomycin sulfate continues to produce significant amounts of fibroblast growth factor even after Bleomycin sulfate is removed and replaced with fresh (Bleomycin sulfate-free) media. Fibroblast growth factor secretion by Bleomycin sulfate-stimulated alveolar macrophages is inhibited by cycloheximide, and the 5-lipoxygenase inhibitors NDGA (nordihydroguaiaretic acid) and BW755c, indicating not only a requirement for protein synthesis but also for metabolites of the 5-lipoxygenase pathway of arachidonic acid metabolism for full expression of activity. [2] Bleomycin sulfate (400 µg/mL) incubation for 24 hours decreases the viability of NTera-2 cells, and increases caspase-3, -8 and -9 activities, Bax and cytoplasmic cytochrome c levels and decreases Bcl-2 levels. [3] In terms of unstable aberrations, the clastogenic effect of Bleomycin sulfate on ADIPO-P2 cells persists for at least 10 days after exposure. Bleomycin sulfate-induced telomere instability in mammalian cells persists for several generations after exposure. Moreover, the appearance of telomere fusions in Bleomycin sulfate-exposed cells 10 days after treatment suggests that Bleomycin sulfate can induce delayed telomere instability. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
F98 M1HwOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX6w5qCUOTByMDFOwI0> MWCyOEBpyqB? M1\TNYlvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> NHvqSIwzPjB6OEexNS=>
POLK WT NVTUbpM4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfkc45iUUN3ME2xNU446oDLwsJihKkyNjgEoN88US=> NGC5UVMzPjB|MUSwNC=>
POLK KO NXm1d402T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVi1RZR{UUN3ME20MlA{6oDLwsJihKkyNjl{wrFOwG0> NYDVSllyOjZyM{G0NFA>
POLK CD NU\xZmx2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV76N|Q1UUN3ME21MlU66oDLwsJihKkyNjBywrFOwG0> M3Syb|I3ODNzNECw
RLE/Abca3 M3faT2Z2dmO2aX;uJGF{e2G7 MWmwMlTDqM7:TR?= MYWxOFTDqGh? MonBbY5lfWOnczDhJI1wenCqb3zv[4lk[WxiY3jhcodmKG[{b32g[ZBqfGinbHnhcE1tcWunIH3vdpBpd2yxZ4mgeI8h[SC5aXTlMEB{eHKnYXStc5V1KG2xcoDoc4xw\3oEoB?= NWLlSWRvOjV5NkC1N|g>
PMCs MmHUSpVv[3Srb36gRZN{[Xl? M4\lPVAvOeLCk{NCpO69\y:vbB?= MYOyOOKhcA>? MWLjZZV{\XNiYTDkc5NmNWSncHXu[IVvfCCrbnPy[YF{\SCrbjD0bIUheHKxdHXpckBt\X[nbDDv[kBkd2yuYXflck1KyqB? MmrHNlU2QTV4NEK=
PMCs NUPJPJp2TnWwY4Tpc44hSXO|YYm= M17xflAvOsLizsznM41t NHzhWGQzPOLCk{eyxsBp NFe4N|RqdmS3Y3XzJIlv[3KnYYPld{BqdiC4aX3lcpRqdiCjbnSg{tEuW02DIIDyc5RmcW5? MmfVNlU2QTV4NEK=
PMCs MUHGeY5kfGmxbjDBd5NigQ>? NUPYSGJvOC5{wrFOwIcwdWx? NHzpVpU4OiCq M3raOYlv\HWlZYOg[IVkemWjc3XzJIlvKGO7dH;r[ZJifGmwLUigZY5lKEVvY3HkbIVzcW5icILveIVqdg>? MlHsNlU2QTV4NEK=
PMCs NEPZV41HfW6ldHnvckBCe3OjeR?= NG[3V4cxNjMEoN88[{9udA>? M2LlSVEzNzJ2L{S4JIg> NVXMTW95cW6lcnXhd4V{KGOnbHygcYloemG2aX;u NVTLPJBUOjV3OUW2OFI>
IMR-32 Mn;MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVG5SFFRPy534pkSNVIxKML3Zz;tcC=> NITFdZEyOuLKkkS4JIg> M{fOemlEPTB;NkCgxtVoN22uIHH0JJRp\SCnbnSgc4YhOjRiaILzJI9nKGmwY4XiZZRqd25? NW\nfWkyOjV3M{[zOFU>
HT1080 NUXqVG1IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWmxJO69VQ>? Ml\1NlQhcMLi M4r5doxm[WS|IITvJIEhTzJxTTDk[YxigQ>? MViyOVUyQDl4MR?=
HT1080 M2fkfWZ2dmO2aX;uJGF{e2G7 NX7lZpR2OSEQvF2= NWPmdnhrOjRiaNMg MoLzbY5lfWOnczDhJJBwfGWwdDDncI9j[WxiRF7BJIRidWGpZTDy[ZNxd26|ZR?= MoLWNlU2OTh7NkG=
HDFn NXv6WGVnS3m2b4TvfIlkcXS7IFHzd4F6 NXm3botRPzJiaB?= NVjmd2NiUUN3ME25MlMyLcLi MoC0NlUzPzZ5OUK=
THP-1 M1rqcmN6fG:2b4jpZ4l1gSCDc4PhfS=> NWraRlVXPzJiaB?= NFfS[JJKSzVyPUSuO|cm NHX0VpUzPTJ5Nke5Ni=>
HT-29 NFL2NnVEgXSxdH;4bYNqfHliQYPzZZk> MX[3NkBp MmT5TWM2OD1zMT60PUU> MWGyOVI4Pjd7Mh?=
HCT116  NXjye2g4S3m2b4TvfIlkcXS7IFHzd4F6 MojoO|IhcA>? MnjhTWM2OD1zMT6zOEU> M2nqbFI2Ojd4N{my
A431 MknOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXOOVAuOjByIFnV NYXNVVE{PDkkgJno NHv6SVJqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 M3PiOlI2OTBzMkm5
T24 M{HkRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV61NE0zODBiSWW= MoTMOFjjiImq Ml3ubY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> MorLNlUyODF{OUm=
AY-27  NHH6cXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jyelUxNTJyMDDJWS=> NELu[ZM1QOLCiXi= MVjpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 M4XLXVI2OTBzMkm5
A549 NW\tcZZOTnWwY4Tpc44hSXO|YYm= MXSxJOK2\y:vTNMg NUnQeI5MOC12ODDo Mo[ybY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mxsBQWE8EoH3SUmE> MXGyOFk3OzZ|NR?=
MLE12 NYnMcWxNTnWwY4Tpc44hSXO|YYm= M4P2eVEhyrWpL33MxsA> MkfSNE01QCCq MmnFbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mxsBQWE8EoH3SUmE> MkTuNlQ6PjN4M{W=
Jurkat NED2e|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfYT5I4OjEkgJpOwI0> NFjt[HczPOLCiXlCpC=> Mnv1ZZJz\XO2czD0bIUh[2WubDDjfYNt\SCjdDD0bIUhTzJicHjhd4U> NUjaN|d5OjR7MU[4PVM>
HeLa  NYrEWINmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTFyLkNCpO69VQ>? NWC2emZtOjR5M{KzPVc>
C18-4 M4L1WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnTelVjOC1zMECg{txO MWHpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 M4jqb|I1PTdzOUiy
BMG-1  NYfve3JLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFj3SmE1OC96MNMg{txoN21? M1;iR|PDqGh? MnPibY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> MV2yN|kxPjd{Nh?=
A459 MljyRZBweHSxc3nzJGF{e2G7 NGTEUHEyOCCvVR?= Mk\zOFghcA>? NFr2RVdqdmS3Y3XzJIFxd3C2b4Ppdy=> MojsNlM6ODJ5Nk[=
MOCK NWLmemx1SXCxcITvd4l{KEG|c3H5 NXjBPJdXOTBibWW= NWDBb3RYPDhiaB?= MoHMbY5lfWOnczDhdI9xfG:|aYO= NH\2OmYzOzlyMke2Oi=>
MMP1 MWrBdI9xfG:|aYOgRZN{[Xl? MYexNEBuXQ>? MX[0PEBp NFfKVFdqdmS3Y3XzJIFxd3C2b4Ppdy=> NXf4SXBVOjN7MEK3OlY>
A549 NWOxXFhtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWWyNFAh|ryP NXLRNVg6OjRiaNMg NVXab|VU\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJNq\26rZnnjZY51dHl? MlfGNlM5ODV5OUO=
HCT-116 Ml;VRZBweHSxc3nzJGF{e2G7 NGThSm8{NzdwNT:xOUDPxGdxbXy= NXrrVGFsPDhiaB?= MUDy[YR2[2W|IITo[UBt\X[nbDDv[kBDVEhiYYSgbIlocCClb37j[Y51emG2aX;u MV2yN|cxQDZ4OB?=
HeLa NWDzPG5iSXCxcITvd4l{KEG|c3H5 NIfmNnk{NzdwNT:xOUDPxGdxbXy= MYq0PEBp MoTGdoVlfWOnczD0bIUhdGW4ZXygc4YhSkyKIHH0JIhq\2hiY3;uZ4VvfHKjdHnvci=> NY\JRmpuOjN5MEi2Olg>
HCT116 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXKNE0yODBizsznM41t NX3vVYdzPDhiaB?= NF7WdpdqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 NWHDdVRNOjN3MUiyNFE>
NCM460 NEDScJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLUNE0yODBizsznM41t MoHlOFghcA>? NWT0OoFUcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? MWmyN|UyQDJyMR?=
NT2  M3PCSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXn2d5ZOOjRiaNMg NXXE[5lKVER3ME20NFDjiIoEtXevcYw> NWrlVmFuOjN|OE[0NlA>
NT2  NHzi[WdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV60PEBp M3PnN2xFPTB;MUCwJOK2\y:vbB?= M4TIOFI{Ozh4NEKw
NT2  M1LyZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\jdGU1PzJiaB?= M37mU2xFPTB;MkFihKnDvWdxbXy= MnL5NlM{QDZ2MkC=
NT2  MWjBdI9xfG:|aYOgRZN{[Xl? MnTHOFAx6oDLwsXnM41t NXznTFN{OjRiaNMg M2f2SIlv\HWlZYOgd4lodmmoaXPhcpQhcW6lcnXhd4V{KGmwIHPhd5Bie2VvMzy4MFkh[WO2aY\peJnDqA>? MXmyN|M5PjR{MB?=
NTera-2 MmTuSpVv[3Srb36gRZN{[Xl? NYOyb|R[OTJyIN88[{9udA>? MUi3NkBp NFvUcVV{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczC4MYl{d3C{b4P0ZY5mKGyndnXsdy=> NHXQVpYzOjh{NUO1OS=>
NCCIT M{\wcmZ2dmO2aX;uJGF{e2G7 MX[xNlAh|rypL33s MlHrO|IhcA>? M{Dhe5Nq\26rZnnjZY51dHliaX7jdoVie2W|IEitbZNweHKxc4ThcoUhdGW4ZXzz MYeyNlgzPTN3NR?=
NTera-2 Mke1SpVv[3Srb36gRZN{[Xl? NEjF[m0yOjBizsznM41t NUDkOI5WPzJiaB?= MVzzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyCWQlHSV{Bt\X[nbIO= MYeyNlgzPTN3NR?=
NCCIT MknmSpVv[3Srb36gRZN{[Xl? M4DaW|EzOCEQvHevcYw> NUXj[WhmPzJiaB?= M2fTRpNq\26rZnnjZY51dHliaX7jdoVie2W|IGTCRXJUKGyndnXsdy=> Mmj5NlI5OjV|NUW=
NCCIT M2jnd2Z2dmO2aX;uJGF{e2G7 Mn7VNVIxKM7:Zz;tcC=> NVi3dHYyPzJiaB?= MoDJd4lodmmoaXPhcpRtgSCmZXPy[YF{\XNiR2PIJIxmfmWucx?= Mn;1NlI5OjV|NUW=
NTera-2 NWHiXWxWTnWwY4Tpc44hSXO|YYm= MYixNlAh|rypL33s M3LFfVczKGh? NGe1SGh{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDQdo91\WmwIHPhdoJwdnmuIHzleoVtew>? NF;ZcYszOjh{NUO1OS=>
NCCIT NF7y[YdHfW6ldHnvckBCe3OjeR?= NHvHWZoyOjBizsznM41t M1K1b|czKGh? MUDzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyCScn;0[YlvKGOjcnLvcpltKGyndnXsdy=> M4PEUFIzQDJ3M{W1
NTera-2 M2\5SGZ2dmO2aX;uJGF{e2G7 MnWxNVIxKM7:Zz;tcC=> MWe3NkBp NGPwdpp{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDMVG8hdGW4ZXzz NX7K[4VYOjJ6MkWzOVU>
NCCIT NV\uZphLTnWwY4Tpc44hSXO|YYm= NGjrWY8yOjBizsznM41t NEPVUJM4OiCq NHLP[ll{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDMVG8hdGW4ZXzz MljRNlI5OjV|NUW=
MDA-MB-468 M2PqWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnqyNQKBmzJyMNMg{txoN22O NV7IWItEOjRiaB?= MXnpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 NHz3VmozOjhzOUG5Oi=>
231-H2N NHfNNHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M123S|DjiJN{MEFCpO69\y:vTB?= M3rxUlI1KGh? MXXpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 MWWyNlgyQTF7Nh?=
A549  MXvGeY5kfGmxbjDBd5NigQ>? NH3ifJAzODBxNECwJO69VQ>? NUXrdGNvemW|dXz0d{BqdiCjIHTvd4UuemW|cH;ud4l3\SCrbnPy[YF{\SCrbjDSU3M> M4PFOlIzPzd|Nkm3
A549  MVLGeY5kfGmxbjDBd5NigQ>? MUewMVQxOCEQvF2= M1zYUVIuPDhiaB?= MYjjZZV{\XNibX;y[UBufESQQTD0bIFvKG6GTlGg[IFu[Wen NXi5[HpYOjJ5N{O2PVc>
A549  NFGwRoRHfW6ldHnvckBCe3OjeR?= NEXoTooyODBizszNxsA> NYjZW|JWOOLCk{S4JIg> M3:w[4NifXOnczDjZZNx[XOnLUOgZYN1cX[jdHnvci=> M1;yRVIzPzd|Nkm3
A549  NH2zPYRHfW6ldHnvckBCe3OjeR?= MXWxNFAh|ryPwrC= NFfsOGUx6oDVNEigbC=> MVTjZZV{\XNiUFvENUBkdGWjdnHn[S=> MWqyNlc4OzZ7Nx?=
A549  M{\UeGZ2dmO2aX;uJGF{e2G7 MlfaNVAxKM7:TdMg M2XjfFDjiJN2ODDo M4HJSYNifXOnczDtbZRw[2ixbnTybYFtKGyxY3HsbZpifGmxbjDv[kBD[Xh? M{TqeVIzPzd|Nkm3
A549  MXTGeY5kfGmxbjDBd5NigQ>? MVOxNFAh|ryPwrC= NIn6dFEx6oDVNEigbC=> MnHU[IVkemWjc3XzJG1OWCCjbnSgRXRRKGyndnXsdy=> MWOyNlc4OzZ7Nx?=
MCF-7/Her-18  M3\nbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfET44xNjR{LUG3NFAh|rypL33M M37TVVI1KGh? MnHQbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> NWGx[ld3OjJ4MkG0NFQ>
MCF-7 NV\V[YZUWESWL2DDTUBVemWjdH3lcpQ> NGCzb5MxNjJ3IN88[{9udC5? MWixMVQhcA>? M13FZpNpd3e|IIPp[45q\mmlYX70JEhRyqB:IECuNFUqKGO7dH;0c5hq[yCnZn\lZ5Q> M4TaWlIzPTlzMki0
MDA-MB-231 NEjQWmlRTFRxUFPJJHRz\WG2bXXueC=> MlfyNE4zPSEQvHevcYwv NFn5Zm4yNTRiaB?= NVn1PXE6e2ixd4Ogd4lodmmoaXPhcpQhMFEEoEygNE4xPSliY4n0c5RwgGmlIHXm[oVkfA>? MnHnNlI2QTF{OES=
MDA-MB-235  M1LKdHBFXC:SQ1mgWJJm[XSvZX70 NHPqXHIxNjJ3IN88[{9udC5? MkjSNU01KGh? MmPid4hwf3Nic3nncolncWOjboSgLHDDqDxiMD6wOUkh[3m2b4TvfIlkKGWoZnXjeC=> M1fOdlIzPTlzMki0
MCF-7 NGfOSotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LLWVAuOiEQvHevcYwv MUKyOE81QCCq M3\pTWVEPTB;MT6yJO69\y:vTB?= NUDMXVR7OjJ3OUGyPFQ>
NCCIT  M{T0O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXwNlDjiJNzNEFCpO69\y:vbB?= NWfpfXdzPzJiaB?= NVz5SWhVVER3ME2xNlDDqM7:Zz;tcOKh M4PtOFIzPTZ{MU[w
NCCIT  MoTCSpVv[3Srb36gRZN{[Xl? NUTRfHNUPzJiaB?= MXfzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyClYYPwZZNmNTNiYXP0bZZqfHoEoB?= MUKyNlU3OjF4MB?=
NCCIT  NEDKZ4VHfW6ldHnvckBCe3OjeR?= MXu3NkBp M33o[JNq\26rZnnjZY51dHliaX7jdoVie2W|IHPhd5Bie2VvODDhZ5Rqfmm2edMg MVyyNlU3OjF4MB?=
NCCIT  MmrHSpVv[3Srb36gRZN{[Xl? NHrZN2M4OiCq M{LQXJNq\26rZnnjZY51dHliaX7jdoVie2W|IHPhd5Bie2VvOTDhZ5Rqfmm2edMg NIHBcpMzOjV4MkG2NC=>
NCCIT  MnTPSpVv[3Srb36gRZN{[Xl? MXm3NkBp MYrzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyCEQWigcIV3\Wx? MmLQNlI2PjJzNkC=
NCCIT  MYXGeY5kfGmxbjDBd5NigQ>? Mk\lO|IhcA>? NYDubIMze2mpbnnmbYNidnSueTDk[YNz\WG|ZYOgeIhmKEKlbD2yJINwdnSnboS= NHnsbYozOjV4MkG2NC=>
NCCIT  NWfRRnVVTnWwY4Tpc44hSXO|YYm= NXzqV5REPzJiaB?= MUXzbYdvcW[rY3HueIx6KGSnY4LlZZNmeyC2aHWgR5l1NWNibHX2[Yw> NF\QTlgzOjV4MkG2NC=>
HeLa NEnteIhHfW6ldHnvckBCe3OjeR?= M2XRV|MxNzdyIN88[{9udA>? M4fPSVI1yqCq NX3jc3g1cW6lcnXhd4V{KHSqZTDtVm5CKGyndnXsd{Bw\sLicEWz89yNSVSPLICyNeKh[W6mwrDHRWRFPDV? M3n1cFIzPDh5OUO3
MCF-7  MUjGeY5kfGmxbjDBd5NigQ>? MorXN|AwPzBizsznM41t M17Nd|I1yqCq M3rE[4lv[3KnYYPld{B1cGVibWLORUBt\X[nbIOgc4bDqHB3M,-8kGFVVSyyMkJCpIFv\MLiR1HESFQ2 NGC1OWwzOjR6N{mzOy=>
HeLa MVvDfZRwfG:6aXPpeJkhSXO|YYm= NYq5V4cyOzBxN{Cg{txoN22u MWSyOOKhcA>? MWHpcoR2[2W|IHjp[4htgSC|aXfubYZq[2GwdDDs[ZZmdHNib3[g[pJi\22nboTl[EBFVkFicnXs[YF{\SCrboTvJJRp\SCleYTvdIxie21? Mnn5NlI1QDd7M{e=
MCF-7  NGntVYxEgXSxdH;4bYNqfHliQYPzZZk> M3SyeFMxNzdyIN88[{9udA>? MWSyOOKhcA>? NYXlRY9ZcW6mdXPld{BpcWeqbImgd4lodmmoaXPhcpQhdGW4ZXzzJI9nKG[{YXft[Y51\WRiRF7BJJJmdGWjc3WgbY51dyC2aHWgZ5l1d3CuYYPt NEG5fpMzOjR6N{mzOy=>
NT2 MojBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXNdpUyODBvNkCwxsDPxGdxbXy= M2HQT|I1KGh? NIP2SY1KSzVyPUSwNEDDvWdxbXy= MoPmNlI1Pjl7NUK=
NT2 Mn\USpVv[3Srb36gRZN{[Xl? MUS0NFDDqM7:Zz;tcC=> NFLFV3kzPCCq NFztenR{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDjZZNx[XOnLUOsPEw6KGGldHn2bZR6yqB? MYiyNlQ3QTl3Mh?=
NT2 MkDQSpVv[3Srb36gRZN{[Xl? M3m1W|QxOMLizsznM41t NVv0fWxCOjRiaB?= NWDiXYk6e2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgRmFZKGyndnXs MmHhNlI1Pjl7NUK=
NT2 NWnBXWs2TnWwY4Tpc44hSXO|YYm= NIXRb|M1ODEEoN88[{9udA>? NInRfo8zPCCq NEXsbIh{cWewaX\pZ4FvfGy7IHTlZ5Jm[XOnczDCZ4wuOiCuZY\lcC=> M12wdlIzPDZ7OUWy
CHO NGXhNXBHfW6ldHnvckBCe3OjeR?= MkHzNk42yqEQvHevcYw> MoPuNVghcC94IHS= NFHIZXVqdmS3Y3XzxsBx\XK|aYP0[Y5k\SCxZjDjbJJwdW:|b33lJIRidWGpZR?= NFjBOnUzOjJ|MEG5OS=>
Jurkat M1fOcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfPeIkxNTFyMNMg{txoN22u MXKyOEBp MUDhdpJme3S|IITo[UBk\WyuIHP5Z4xmKGG2IITo[UBIOiCyaHHz[S=> M{jqNVIzOjJ|M{Oy
Jurkat NGW4VpBHfW6ldHnvckBCe3OjeR?= NV\2PYhMOzEEoN88[{9udA>? Mk\xNlQhcA>? M1zaRYlv[3KnYYPld{B1cGVicILveIVqdiCuZY\lcJMhd2ZiY4njcIlveyCGMzygRUBidmRiQkG= M{G4cFIzOjJ|M{Oy
Jurkat NVvYV45WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{G0S|AuOTBywrFOwIcwdWx? NH\yUo4zPCCq NIe5PZhqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZIhf2m2aDDhckBKSzVyII\hcJVmKG:oIEGwNO69\y:vTB?= MXiyNlIzOzN|Mh?=
Jurkat MWLGeY5kfGmxbjDBd5NigQ>? MoGxN|DDqM7:Zz;tcC=> M370T|I1KGh? MorKbY5kemWjc3XzJJRp\SCnZn\lZ5Qhd2ZicInjcollcW:wZTDvckBxcG:|cHjvdplt[XSrb36gcIV3\Wy|IH;mJIhqe3SxbnWgTFJCNlh? MWWyNlIzOzN|Mh?=
U2OS EGFPnls M4\KTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXQV3ltOC1{wrFOwIcwdWx? Mny0NlQhcA>? NGni[FFqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 NXT3Z41UOjF6MUGwNFc>
U2OS KuEnls NGn4bYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU[wMVLDqM7:Zz;tcC=> NVL6VW9ZOjRiaB?= MVPpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 Ml;BNlE5OTFyMEe=
MCF-7 MlS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfqRlExNTRyMDFOwG0> NIXPPWU4OiCq MknJUGM2OD1zNUGuPOKh|ryP NET3[mYzOTdyM{K5NS=>
MCF-7/Adr  NVfJeoNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TCeFAuPDByIN88US=> NFW3bWc4OiCq MnzGUGM2OD13OD61xsDPxE4EoB?= M3i5RVIyPzB|Mkmx
WI-38 NX7MbWdJTnWwY4Tpc44hSXO|YYm= M1\rZVAwPDBxOEFihKnPxGdxbX|CpC=> NF7pZ5Q{KGh? MVTpcoR2[2W|IHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRiaX7jdoVie2ViaX6geIhmKE2QIH\y[ZF2\W6ledMg NWnSfIpDOjF3OUm2NVI>
hBMSC NULMWYFxTnWwY4Tpc44hSXO|YYm= NEjpRlUxNzRyL{iw5qCK|rypL33sxsA> MUmzJIg> MWLpcoR2[2W|IHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRiaX7jdoVie2ViaX6geIhmKE2QIH\y[ZF2\W6ledMg NGHvU2czOTV7OU[xNi=>
NCI-H23 M{WzU2Z2dmO2aX;uJGF{e2G7 NHnvSoExNzRyL{iw5qCK|rypL33sxsA> MlzJN{Bp MmrRbY5lfWOnczDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IHnuZ5Jm[XOnIHnuJJRp\SCPTjDmdoVyfWWwY4pCpC=> NVW5cXR[OjF3OUm2NVI>
A-549 MX3GeY5kfGmxbjDBd5NigQ>? M{\IRlAwPDBxOEFihKnPxGdxbX|CpC=> MYGzJIg> NIfocWtqdmS3Y3XzJIEh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgbY5kemWjc3WgbY4hfGinIF3OJIZz\XG3ZX7jfeKh MYmyNVU6QTZzMh?=
PBL  NX3ReFJETnWwY4Tpc44hSXO|YYm= NFHxVnQxNzRyL{iw5qCK|rypL33sxsA> NFrhfnU{KGh? NYHSbo5ZcW6mdXPld{BiKGOxbnPlcpRz[XSrb36t[IVx\W6mZX70JIlv[3KnYYPlJIlvKHSqZTDNUkBnemWzdXXuZ5nDqA>? MkTrNlE2QTl4MUK=
pol β −/− MoHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;qS2MxNjJ3LUKwNOKh|rypL33s M1\FXFI1yqCq NGTEZlRl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImge4l1cCCrbnPy[YF{cW6pIHPvcoNmdnS{YYTpc45{yqB? M{n0Z|IyOjVzOUS0
pol β +/+ NX7ueZhJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XYdlAvOjVvMkCwxsDPxGdxbXy= M2PVbVI1yqCq MkLX[IVkemWjc3XzJINmdGxidnnhZoltcXS7IIfpeIghcW6lcnXhd4lv\yClb37j[Y51emG2aX;ud:Kh MlfzNlEzPTF7NES=
pol β −/− NVqxSI1{TnWwY4Tpc44hSXO|YYm= NF\QWI0xNTJwNTFOwIcwdWx? MknBNkBp NXnWR|hS[2G3c3XzJGRPSSCmYX3h[4U> MmS5NlEzPTF7NES=
pol β +/+ MmLxSpVv[3Srb36gRZN{[Xl? MXqwMVIvPSEQvHevcYw> NEC3[5czKGh? MlfIZ4F2e2W|IFTORUBl[W2jZ3W= MVeyNVI2OTl2NB?=
pol β −/− MnLsSpVv[3Srb36gRZN{[Xl? MnHzNE02KM7:Zz;tcC=> MWG0PEBp MWHjZZV{\XNibXnjdo9vfWOuZYXzJIRwe2ViYX7kJJRqdWViZHXw[Y5l\W62bIm= NY\XfphSOjF{NUG5OFQ>
pol β +/+ NWjxUFdLTnWwY4Tpc44hSXO|YYm= NH;1NWYxNTVizsznM41t MWC0PEBp M{nV[oNifXOnczDtbYNzd263Y3zleZMh\G:|ZTDhcoQhfGmvZTDk[ZBmdmSnboTsfS=> MofFNlEzPTF7NES=
TK6  MkHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjhclhDOjVvMUWwJO69\y:vbB?= NXXp[G14QTZiaB?= MYfpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 NWLuV3VqOjFyOEG0PFc>
TK6  sLUC+Apn1 NF\Kc5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnGzNlUuOTVyIN88[{9udA>? NImxfpA6PiCq NFz4W21qdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 NUDCeXVpOjFyOEG0PFc>
TK6 sAPE1+Apn1 NHTlTGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXGyOU0yPTBizsznM41t NE[wTZY6PiCq M3;wdZNq\26rZnnjZY51dHliaX7obYJqfHNiY3XscEBoem:5dHig[I9{\SCmZYDlcoRmdnSueR?= MVqyNVA5OTR6Nx?=
HCT116 MlLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzmUFQzPS1zNUCg{txoN22u MVS5OkBp MXHpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 M1rvTFIyODhzNEi3
HCT116 sLUC+Apn1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1:yblI2NTF3MDFOwIcwdWx? MmmwPVYhcA>? NInZUWlqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 MX2yNVA5OTR6Nx?=
HCT116 sAPE1+Apn1 NVHhN|VkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHwNlUuOTVyIN88[{9udA>? MWm5OkBp M1TCeZNq\26rZnnjZY51dHliaX7obYJqfHNiY3XscEBoem:5dHig[I9{\SCmZYDlcoRmdnSueR?= M1rE[lIyODhzNEi3

... Click to View More Cell Line Experimental Data

In vivo Day 7 post-Bleomycin sulfate, CD45+ cells in BALf in NOX-/- is 1.7-fold > WT, 57% of which are Mf that decreases by 67% in WT and 83% in NOX-/- by Day 21. [5]

Protocol

Cell Research:

[4]

+ Expand
  • Cell lines: ADIPO-P2 cells
  • Concentrations: 2.5 μg/mL
  • Incubation Time: 30 minutes
  • Method:

    ADIPO-P2 cells are grown in D-MEM high glucose medium supplemented with 20% fetal calf serum, penicillin (100 U/mL) and streptomycin (100 μg/mL) at 37 °C and 5% CO2 atmosphere. Cells are cultured as monolayer in TC25 Corning flasks containing 1.5 × 105 cells/mL. For each experiment, two flasks are set up, one for the control and one for the treated culture. During the log phase of growth ADIPO-P2 cells are treated with a 30 minutes pulse of 2.5 μg/mL of Bleomycin sulfate. Control cultures are set up in parallel but not exposed to Bleomycin sulfate. Time of exposure and concentration of Bleomycin sulfate are chosen according to previous studies carried out in our laboratory with mammalian cells exposed to Bleomycin sulfate. At the end of the pulse treatment with Bleomycin sulfate, the cells are washed twice with Hank's balanced salt solution and kept in culture with fresh culture medium until harvesting. Cells are continuously maintained in culture during 5 passages or subcultures after treatment. Subcultivation is carried out whenever the cultures became confluent (approximately 4 × 105 cells/mL of culture medium). To estimate cell growth, at the time of subcultivation cells are collected by trypsinization, an aliquot of about 200 μL stained with 0.4% trypan blue, and the number of viable cells is determined. Cells are then suspended in fresh culture medium and dispensed into new culture flasks containing 1 × 105 cells/mL to continue growing. The rest of the cells is discarded or dispensed in another flask for cytogenetic analysis, which is performed at 18 hours and 10 days after the end of treatments. To analyze chromosomal aberrations, colchicine (0.1 μg/mL) is added to cell cultures during the last 3 hours of culture. Chromosome preparations are made following standard procedures. After harvesting, cells are hypotonically shocked, fixed in methanol:acetic acid (3:1), spread onto glass slides and processed for PNA-FISH. Two independent experiments are carried out.


    (Only for Reference)
Animal Research:

[7]

+ Expand
  • Animal Models: CD-1 mice
  • Formulation: Saline
  • Dosages: 5 mg/kg, 2 ml/kg
  • Administration: Administered via i.t.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL warmed (66.11 mM)
Water 100 mg/mL (66.11 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
Saline
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 1512.62
Formula

C55H85N17O25S4

CAS No. 9041-93-4
Storage powder
Synonyms NSC125066

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02166463 Recruiting Classical Hodgkin Lymphoma|Stage IIB Hodgkin Lymphoma|Stage IIIB Hodgkin Lymphoma|Stage IVA Hodgkin Lymphoma|Stage IVB Hodgkin Lymphoma National Cancer Institute (NCI) March 2015 Phase 3
NCT02582697 Recruiting Germ Cell Tumor University of Sydney|Australian and New Zealand Urogenital and Prostate Cancer Trials Group|Cambridge University Hospitals NHS Foundation Trust|Cancer Trials Ireland|Childrens Oncology Group|Dana-Farber Cancer Institute|University of Southern California February 2014 Phase 3
NCT01390584 Recruiting Lymphoma Eastern Cooperative Oncology Group|National Cancer Institute (NCI) April 2012 Phase 2
NCT01132807 Active, not recruiting Lymphoma Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) May 2010 Phase 2
NCT01042522 Recruiting Ovarian Granulosa Cell Tumor|Ovarian Gynandroblastoma|Ovarian Sertoli-Leydig Cell Tumor|Ovarian Sex Cord Tumor With Annular Tubules|Ovarian Sex Cord-Stromal Tumor|Ovarian Sex Cord-Stromal Tumor of Mixed or Unclassified Cell Types|Ovarian Steroid Cell Tumor Gynecologic Oncology Group|National Cancer Institute (NCI) February 2010 Phase 2
NCT01026220 Active, not recruiting Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma|Stage III Childhood Hodgkin Lymphoma|Stage IV Childhood Hodgkin Lymphoma Childrens Oncology Group|National Cancer Institute (NCI) December 2009 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How about the strength of Bleomycin Sulfate(S1214) in terms of Units/mg?

  • Answer:

    Our S1214 Bleomycin Sulfate is 1500 Units/mg.

  • Question 2:

    what is the ratio between bleomycin A2 and bleomycin B2 in your product?

  • Answer:

    The content of Bleomycin A2 and Bleomycin B2 is 62% and 29% respectively.

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Bleomycin Sulfate | Bleomycin Sulfate ic50 | Bleomycin Sulfate price | Bleomycin Sulfate cost | Bleomycin Sulfate solubility dmso | Bleomycin Sulfate purchase | Bleomycin Sulfate manufacturer | Bleomycin Sulfate research buy | Bleomycin Sulfate order | Bleomycin Sulfate mouse | Bleomycin Sulfate chemical structure | Bleomycin Sulfate mw | Bleomycin Sulfate molecular weight | Bleomycin Sulfate datasheet | Bleomycin Sulfate supplier | Bleomycin Sulfate in vitro | Bleomycin Sulfate cell line | Bleomycin Sulfate concentration | Bleomycin Sulfate nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID